Bayer is collaborating with the TB Alliance in the fight against TB

In 2005, in conjunction with Bayer AG, the TB Alliance launched an historic clinical trial program to test whether Bayer’s moxifloxacin can be used to significantly shorten the time it takes to cure TB.

The TB Alliance is a non-profit organization, a partnership of public and private institutions which cooperate on an international level with research facilities and universities. As a drug developer the TB Alliance is working exclusively to find a faster and affordable TB cure.

If successful, their trial program could result in the first new drug approved for tuberculosis in over forty years. The investigators are optimistic about their chances of achieving good results with the antibiotic moxifloxacin supplied by Bayer. The study has enrolled 3,000 TB patients on four continents to investigate whether the drug is also suitable for treating tuberculosis.

Further information


Partnership types

Provision of services / personnel; Provision of goods

Global issues

HIV/AIDS, TB, malaria, health and medical

Business sectors

Medical and health